What Noscendo does

Noscendo GmbH is a German in-vitro diagnostics company headquartered in Duisburg, founded in 2018. The company has developed DISQVER®, a CE-marked and IVDR-marked diagnostic test that uses next-generation sequencing (NGS) technology to detect pathogens responsible for life-threatening infections when conventional diagnostic methods are insufficient. DISQVER® is built on proprietary NGS-based diagnostic software that processes sequencing data to identify pathogens, and represents Noscendo's sole product offering. The platform is supported by a comprehensive regulatory and quality compliance framework, including ISO 13485 (BSI), ISO 27001, HIPAA, and GDPR certifications, enabling clinical use across the EU and positioning the company for US healthcare engagement.

The company operates a B2B enterprise go-to-market, selling DISQVER® directly to hospitals, clinical laboratories, and medical centers on a quote-based, multi-year contract basis. Revenue is generated through one-time licensing of the diagnostic test. Noscendo targets physicians and medical disciplines through content marketing, scientific publications, and industry events. The company is privately held and venture-backed, having closed a Series B funding round in May 2022 led by Revent, with participation from EarlyBird, HTGF, SquareOne Venture Capital, and Wieland Capital, following an earlier 2020 funding round. Headcount is in the 11-50 range, consistent with an early-commercial-stage venture-backed diagnostics company. No revenue figures, named customers, or pricing details are publicly disclosed.

Name

Noscendo

Legal name

Noscendo GmbH

Website

https://noscendo.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Noscendo GmbH is a German diagnostics company offering DISQVER®, a CE-marked and IVDR-marked NGS-based test that detects pathogens causing life-threatening infections, sold B2B to hospitals and clinical laboratories via enterprise contracts.

Ownership category

akta.pro rank

Product category

Infectious Disease Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• NGS-based diagnostics
• Pathogen detection
• Infectious disease diagnostics
• Clinical sequencing
• In vitro diagnostics

Headquarters

HQ city

Duisburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. DISQVER® Diagnostic Testing: Revenue generated from the sale and provision of the CE-marked DISQVER® diagnostic test to healthcare institutions for detecting life-threatening pathogens

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Noscendo provides the DISQVER® test, a CE-marked and IVDR-marked NGS-based (Next-Generation Sequencing) diagnostic platform that detects pathogens responsible for life-threatening infections. The test is offered to physicians and medical disciplines at hospitals, laboratories, and clinical facilities when conventional diagnostic methods are insufficient. The product is delivered through a B2B sales motion targeting healthcare institutions.

Product overview

Noscendo offers a single unified product: DISQVER®, an NGS-based (Next-Generation Sequencing) diagnostic software platform. DISQVER® is a CE-marked and IVDR-marked in-vitro diagnostic test designed to detect pathogens responsible for life-threatening infections. The company operates exclusively around this core diagnostic product, which represents their complete product and service offering.

Differentiator

Problem solved

Functional benefit

Brands

• DISQVER®: CE-marked NGS-based diagnostic test that detects pathogens responsible for life-threatening infections.

Products and services

• DISQVER® A CE-marked and IVDR-marked NGS-based diagnostic test that detects pathogens responsible for life-threatening infections, utilizing next-generation sequencing technology for comprehensive pathogen identification. Targeted at physicians and medical disciplines at hospitals, laboratories, and clinical facilities.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mobidiag (Hologic): Acquired by Hologic, Mobidiag develops molecular diagnostics for gastrointestinal and respiratory infections. Comparable as a European molecular diagnostics company acquired by a larger incumbent, illustrating a likely strategic exit path for Noscendo.
• Accelerate Diagnostics: Developer of rapid phenotypic and molecular antimicrobial susceptibility testing for serious infections. Comparable in providing hospital-focused diagnostic solutions for life-threatening infections with similar clinical use cases.
• BioMérieux (BioFire FilmArray): Global leader in clinical microbiology and molecular diagnostics, with BioFire FilmArray syndromic panels for rapid pathogen identification. Directly comparable as an NGS/PCR-based pathogen detection platform sold to hospital labs addressing life-threatening infections.
• Curetis (OpGen): Molecular diagnostics company specializing in rapid detection of antibiotic resistance and pathogens for severe infections. Comparable European-rooted peer with similar NGS-based pathogen detection offering for hospital labs.
• T2 Biosystems: U.S.-based diagnostics company developing rapid molecular tests for sepsis and bloodstream infections directly from whole blood. Comparable in addressing NGS/molecular pathogen detection for critical care infections sold to hospital systems.

Emerging players

• Day Zero Diagnostics: U.S.-based startup using whole-genome sequencing and AI to identify pathogens and antibiotic resistance from blood samples. Comparable as an emerging NGS-based sepsis diagnostics company targeting similar clinical applications and customers.
• Inflammatix: Early-stage company developing host-response diagnostics for acute infections and sepsis. Comparable as an emerging diagnostics company addressing rapid pathogen/infection identification for critically ill patients.
• Resistell: Swiss startup developing rapid phenotypic antibiotic susceptibility testing for life-threatening infections. Comparable European emerging player in the infectious disease diagnostics space addressing hospital customers with novel testing technology.

Broad incumbents

• QIAGEN: Large German-headquartered molecular diagnostics and sample-preparation company with broad NGS-based pathogen detection and clinical research offerings. Comparable as a dominant European incumbent that operates across the broader molecular diagnostics space in which Noscendo competes.
• Roche Diagnostics: Global diagnostics giant offering broad molecular and NGS-based infectious disease testing platforms. Comparable as a broad incumbent providing pathogen detection capabilities to hospitals and reference labs, with significantly greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noscendo